Key takeaways
Brilinta (ticagrelor) is an antiplatelet agent used for the prevention and treatment of heart attacks and strokes.
Two alternative antiplatelet agents are available, Plavix (clopidogrel), which is available in a less expensive generic form, and Effient (prasugrel), which has a fast onset of action and high potency.
Aspirin is often used in dual antiplatelet therapy in combination with Brilinta or can be a standalone alternative.
Brilinta (ticagrelor) could be a highly valuable component of one’s medication list. Treatment and prevention of a heart attack and stroke rank at or near the top of most people’s priority lists for their medical care. Antiplatelet agents are a category that has a significant role in the acute treatment of myocardial infarction (MI or heart attack) and stroke, as well as the prevention of these events. Platelets are our clotting cells and are involved in clot formation during MIs and strokes. As a potent antiplatelet agent, Brilinta can help patients avoid clots and maintain normal blood flow, steering them clear of these health complications. Despite the drug’s importance, you may still find yourself looking for alternatives, probably based on cost concerns or adverse effects. The goal here will be to apprise you of other options to consider.
What can I take instead of Brilinta?
Amongst the antiplatelet agents, the members of the class vary in their cost, drug interactions, and Food and Drug Administration (FDA)-approved indications. The variability within the drug class can be a compelling reason to choose one over another or to make a change between antiplatelet agents. Generic options, including the generic version of Brilinta, ticagrelor, could be appealing. Less commonly, the direct oral anticoagulant Xarelto (rivaroxaban) can be used at a low dose for one of the same indications as Brilinta.
RELATED: Brilinta dosages
Compare Brilinta alternatives |
|||
|---|---|---|---|
| Drug name | Price without insurance | SingleCare price | Savings options |
| Brilinta (ticagrelor) | $627 per 60, 90 mg tablets | $31 per 60, 90 mg tablets of generic ticagrelor at CVS | See latest prices |
| Ticagrelor | $454 per 60, 90 mg tablets | $31 per 60, 90 mg tablets of generic ticagrelor at CVS | See latest prices |
| Plavix (clopidogrel) | $641 per 30, 75 mg tablets | $5 per 30, 75 mg tablets of generic clopidogrel at Kroger | See latest prices |
| Effient (prasugrel) | $733 per 30, 10 mg tablets | $20 per 30, 10 mg tablets of generic prasugrel | See latest prices |
| Aspirin | $13 per 90, 81 mg chewable tablets | $12 per 90, 81 mg chewable tablets of generic aspirin at Kroger | See latest prices |
| Aspirin-dipyridamole extended-release (ER) | $486 per 60, 25-200 mg capsules | $48 per 60, 25-200 mg capsules of generic aspirin-dipyridamole ER at CVS | See latest prices |
| Cilostazol | $99 per 60, 100 mg tablets | $9 per 60, 100 mg tablets of generic cilostazol at Walmart | See latest prices |
| Low-dose Xarelto (rivaroxaban) | $805 per 60, 2.5 mg tablets | $48 per 60, 2.5 mg tablets of generic rivaroxaban at CVS | See latest prices |
Prescription drug prices often change. These are the most accurate medication prices available at the time of publication in ZIP code 23666 as of January 8, 2026. The listed price without insurance references the price of brand-name drugs (unless otherwise specified). The listed SingleCare price references the price of generic drugs if available
Top 5 Brilinta alternatives
1. Plavix
Plavix and Brilinta share the same mechanism of action. They both block the adenosine diphosphate (ADP) P2Y12 receptor on platelets, thereby preventing platelet aggregation. The inhibition of platelet clumping means less blood clotting, a result that can help to treat and prevent MIs and strokes. For the most part, the similarities between the two antiplatelet agents end there.
As a non-thienopyridine that does not require metabolic conversion to an active form, Brilinta has the advantages of a faster onset and higher potency compared to Plavix, making Brilinta a favorite in the setting of acute MI. The potency may be a favorable characteristic for individuals with genetic resistance to P2Y12 inhibitors. A shorter duration of action also makes Brilinta easier to stop in advance of surgery. Unlike Brilinta, Plavix may have reduced activity when used concurrently with the commonly used antacid class of proton pump inhibitors (PPIs), such as Prilosec (omeprazole).
Despite the beneficial effects of Brilinta, it has its drawbacks, which may lead you to consider Plavix as an alternative. Lower potency is likely the reason why Plavix has a lower risk of bleeding side effects, a difference that was found to be particularly important in seniors. Economically, the generic form of Plavix, clopidogrel, is less expensive than the generic form of Brilinta, ticagrelor.
Save up to 80% on Plavix with SingleCare
Different pharmacies offer different prices for the same medication. SingleCare helps find the best price for you.
RELATED: What is Plavix?
2. Effient
Effient is another potent inhibitor of the ADP P2Y12 receptor, making it a close cousin of Brilinta and another favorite in the setting of acute MI due to fast onset and high potency. The list of FDA-approved indications for Effient is shorter than that of Brilinta. Nonetheless, it may have some advantages that spark your interest in changing from Brilinta. Effient was found to be more effective in a randomized clinical trial and in a post hoc analysis, both conducted in patients with acute coronary syndromes, a condition characterized by a sudden reduction in blood supply to the heart. Keep in mind that these findings still need to be confirmed with further studies.
Efficacy aside, Effient also avoids one of Brilinta’s common side effects, dyspnea or shortness of breath. It does not, however, eliminate the potential for bleeding events, as both Effient and Brilinta carry a black box warning from the FDA regarding bleeding risk.
3. Aspirin/dipyridamole
At times, aspirin is an over-the-counter alternative to other antiplatelet drugs, but oftentimes, aspirin is used along with other platelet inhibitors. Dual antiplatelet therapy (DAPT) refers to the use of aspirin in combination with another antiplatelet agent, such as Brilinta, Plavix, or Effient. DAPT is commonly instituted after coronary stents are placed and continued for a variable period, typically at the discretion of a cardiology specialist. The role of DAPT in the short-term after a stroke is still being defined as well.
While Brilinta and aspirin are effective for short-term use after a minor stroke, Plavix and aspirin are a more common choice due to their lower cost and greater research support. Likewise, Brilinta is also not chosen for long-term protection against a second stroke due to a paucity of investigation on this use.
If you have had a stroke previously and are looking for an antiplatelet agent to help prevent another stroke, aspirin/dipyridamole could be a better option based on proven efficacy and an advantage over aspirin alone in this setting. Both aspirin and dipyridamole have antiplatelet effects, dipyridamole by blocking adenosine uptake by platelets and aspirin by inhibiting platelet cyclooxygenase. The combination aspirin/dipyridamole is only indicated for use in the prevention of a second stroke and not for coronary event treatment or prevention, so this drug may not be a valid alternative to Brilinta for you if you have heart problems.
4. Cilostazol
Cilostazol is a generic drug that exerts an antiplatelet effect by inhibiting phosphodiesterase 3 and thereby decreasing platelet aggregation. The drug is FDA-approved for intermittent claudication, a type of leg pain caused by reduced circulation due to blockages in peripheral arteries. Off-label, it has also been used for the long-term prevention of a second stroke. This use of cilostazol may be based on supportive studies from Japan and China. However, studies have not proven this benefit in non-Asian ethnic groups, and like Brilinta, it does not have an FDA indication for secondary stroke prevention.
5. Xarelto
Xarelto does have an FDA-approved preventive indication. Xarelto is a direct oral anticoagulant, also known as a blood thinner, that works by preventing blood clots through inhibition of the factor Xa enzyme. It is best known for the treatment of blood clots and prevention of strokes in those with atrial fibrillation. At a much lower dose than in these uses, Xarelto was studied in combination with aspirin and found to be effective for the prevention of cardiovascular events, including strokes, in patients with known coronary artery disease or peripheral artery disease.
If someone has this disease history, low-dose Xarelto could be an alternative to Brilinta, which was combined with aspirin and found to be effective for cardiovascular event prevention in those with coronary heart disease and diabetes. When considering different options, keep in mind that combining two antiplatelet agents or combining an anticoagulant and an antiplatelet agent can increase the risk of major bleeding.
Related: Is it safe to drink alcohol while taking blood thinners?
Natural alternatives to Brilinta
Efforts to prevent a second heart attack or stroke should include non-pharmacologic methods, in addition to prescription drugs. A healthy diet is recommended, including low salt intake. Weight loss can be beneficial. Smoking cessation is critically important.
Dietary supplements have generated interest regarding their potential to lessen the risk of cardiovascular events. Unfortunately, supplementation with vitamin D and vitamin E has not been proven effective. Likewise, supplementing omega-3 fatty acids, or fish oil, was ineffective in lowering the risk of heart attacks.
RELATED: Is it safe to take Brilinta and drink caffeine?
How to switch to a Brilinta alternative
Typically, the stakes are high when Brilinta is in use. A heart attack or stroke could be unfolding or could be at high risk of recurring. For this reason, if you are considering stopping Brilinta or changing to another drug, you must consult with your healthcare provider for medical advice. Discuss what has prompted you to look for alternatives, review all your options, and take into consideration possible side effects. Brilinta does not require tapering off, but the prescribing healthcare professional should provide you with a detailed plan of how to change medication if you arrive at that conclusion. If the cost of the drug is your concern, consider obtaining a SingleCare discount card and presenting it to your pharmacist for assistance.
- Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study, Circulation (2009)
- Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomised, open-label, non-inferiority trial, Lancet (2020)
- Ticagrelor or prasugrel in patients with acute coronary syndromes, New England Journal of Medicine (2019)
- Ticagrelor or prasugrel in patients with non-ST-segment elevation acute coronary syndromes, Journal of the American College of Cardiology (2020)
- Acute coronary syndromes, Mayo Clinic (2025)
- Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA, New England Journal of Medicine (2020)
- Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis, Stroke (2008)
- Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial, Lancet Neurology (2010)
- Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study, Lancet Neurology (2008)
- Ticagrelor in patients with stable coronary disease and diabetes, New England Journal of Medicine (2019)
- 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation (2019)
- Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range, JAMA (1995)
- Smoking cessation for secondary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews (2022)
- Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism (2011)
- Vitamin E supplementation and cardiovascular events in high-risk patients, New England Journal of Medicine (2000)
- Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial, Circulation (2021)